# PNC's Corporate Healthcare Index

**Fourth Quarter 2024** 




PNC's Corporate Healthcare Index (the "Index") is a tool that examines the performance of – and trends within–the entire healthcare ecosystem. S&P launched the S&P 500 Healthcare Sector Index in 1996, but it is comprised of conventional healthcare entities in traditional subsegments. As healthcare becomes more consumer-centric, PNC's Index takes a modernized, non-traditional view of the healthcare landscape, tracking equity performance of the entire ecosystem based on a broad set of criteria.

Healthcare is the largest industry in the United States with an approximate spend of \$4.9T for 2023, nearly 18% of GDP. Healthcare is being redefined and reshaped nearly every day in a variety ways, as new entrants disrupt business models, corporate retailers enter the ecosystem, and healthcare professionals search for new ways to improve the impact and efficiency of care delivery.

- PNC's Corporate Healthcare Index examines 40 of the top public companies driving healthcare industry activity within six key categories: Emerging Trends, Health Technology / IT, Payors, Pharmaceuticals & Life Sciences, Providers, and Supply Chain / OEM.
- The Index is calculated on a market capitalization-weighted basis for direct comparison with both the S&P 500 Index and the S&P 500 Healthcare Sector Index
- In the final stretch of 2024, the Index slightly underperformed the S&P 500 while outperforming the broader S&P 500 Healthcare Sector Index. Share price declines across subsectors were partially mitigated by gains among Emerging Trends companies (see page 3).

### PNC's Corporate Healthcare Index<sup>2,3</sup>



PNC HEALTHCARE 2

#### Market Commentary<sup>4</sup>

#### **Healthcare Industry**

Amidst all the change within healthcare during the past year—including (though not limited to) cyberattacks, workforce challenges, payor-provider tensions over care denials and prior authorizations, market fluctuations, renewed sensitivity to inflation, and the pending transition of a new Administration and Republican-led Congress—the industry has had quite a year!

In fact, healthcare continues to grapple with consumerism and affordability. As Baby Boomers age and Gen Z's care needs evolve, HFMA reports that more Americans fear paying for a health-related bill they can ill-afford vs. contracting a disease and accessing the care needed to treat it.<sup>5</sup> The call for convenience and transparency, particularly through technological advancement (telehealth) and site-of-care shifts (home, outpatient), may (finally) bend the healthcare curve toward the consumer and even improve primary care engagement. While the provider arena has generated a myriad of activity in Q4, other Index subsectors have been impacted by uncertainty and will be influenced through 2025 by the following:

- **Private Equity Pivots (in Healthcare)**: Firms like KKR, Thoma Bravo, etc. are hedging their long-term investments within healthcare services / care delivery with other healthcare tech and healthcare-adjacent companies that may turn/exit quicker than healthcare services. California is the latest state to invoke PE oversight legislation that impacts healthcare services transactions, though, that legislation has stalled. With the new Administration, any regulatory impacts on PE transactions will likely be enforced at the State level.
- **Primary Care Paradox**: While Walmart and Walgreens divest from primary care, Amazon, Kroger, and (to an extent) CVS are forging ahead with their primary care strategies. The industry is also undergoing a recent, but familiar, trend from independent physicians to practices that are employed / supported by other healthcare entities (e.g., health systems). Still, consumers may yet demand primary care services at home and/or digitally, which would account for further site-of-care shifts.
- Workforce Woes: Following the December rate cut, jobs reports for the early part of 2025 will be revealing, especially for the healthcare and government-related sectors. Should employment remain steady, and wage / supply inflation prove more persistent than expected, we will likely see the Federal Reserve take their collective foot off the rate-cut gas.
- Forecast Foresight: Apart from healthcare delivery, some major publicly-traded healthcare companies are reporting shakier outlooks for 2025, predicated on higher utilization and cost, and diminished bonus payments from the Star Ratings program. Managing earnings expectations has led to some share price decline through the fourth quarter, but the ultimate cost impacts from changes in Star Ratings remain to be seen. However, most major insurers are suing CMS to recalculate the ratings with the hopes of recouping some of those potential losses. Some efforts have already proven successful.<sup>10</sup>
- Regulatory Risk: Added and rigorous regulation was introduced by the Biden Administration surrounding cybersecurity, M&A activity, private equity, investment disclosures, tax exemption, Medicare Advantage, etc. However, as the new White House Cabinet coalesces, questions remain on which pieces of legislation will be pursued, and which will either be eased or be eradicated altogether. Consensus is that the new administration will be less restrictive on M&A, prompting more deal flow.

#### Industry Subsectors

#### **Emerging Trends:**

- Walgreens' potential sale to Sycamore Partners signals further potential split of integrated care delivery from retailers.<sup>11</sup> CVS eliminates 2,900 jobs and pivots on Oak Street strategy amid leadership changes<sup>12</sup>
- Baylor Scott and White, Memorial Hermann, Novant, and Providence come together to form Longitude Health, aimed at improving operations and system performance<sup>13</sup>
- Tenet continues pivot away from acute care to more outpatient, receiving ~\$5B from 14 hospital sales in 2024.<sup>14</sup> Sutter lays out plan for \$800M outpatient facility.<sup>15</sup> Advocate invests heavily in extant and adjacent service areas: Atlanta, GA and Chicago, IL for \$70M and \$1B, respectively<sup>16</sup>
- Anthem walks back anesthesia policy on public backlash<sup>17</sup>
- Corporate Venture Capital arms are on the rise and investing in various companies (e.g., Cone Health Ventures / Centivo)<sup>18</sup>
- Citi and Apollo join forces to create a \$25B private credit program for healthcare 19

#### Health Technology / IT:

- While the telehealth and home health pandemic legislation extensions passed, it appears that there will be downstream regulatory risk for both sectors within healthcare. Like many of our peers, we're keeping a close watch for hints on approach from the new Administration
- Remote Patient Monitoring surged during and after Covid but faces additional challenges from coding and billing inconsistencies<sup>20</sup>
- Microsoft, EPIC partner with health systems leveraging AI to reduce burnout<sup>21</sup>
- Hinge Health teams with Amazon to focus on musculoskeletal medicine underscoring the significance of disease-specific care<sup>22</sup>
- Various health systems and other healthcare providers are seeking consults and special "builds" from Salesforce, EPIC, and other CRMs as patient experience continues to be a focus of CMS<sup>23</sup>

#### Payors:

- Some health Insurers (e.g., Cigna) are cutting Medicare Advantage (MA) in certain markets due to overexposure and regulatory pressure. MA is also driving payor share price fluctuation, as Star Ratings yield lawsuits and expected revenue drops in 2025<sup>10</sup>
- Major health plans are leaning into Dual-Eligible Special Needs Plans (D-SNPs) to claw-back some MA margin<sup>24</sup>
- On-/ off-again M&A rumors fuel speculative discussions surrounding scale, leverage, and landscape but lack operational detail, falling short (e.g., Cigna / Humana)<sup>25</sup>
- With more states adopting and ratifying Medicaid expansion, Medicaid reimbursement rate increases are also planned for next year<sup>26</sup>

#### Pharmaceuticals & Life Sciences:

- Intensified regulatory pressure (PBM Act) from FTC and Congress spark fluctuation in the equities market and even facilitate a structural redesign for large PBMs (CVS, UNH, etc.).<sup>27</sup> New uncertainty emerges as Republicans torpedo the Stopgap spending bill two days before the 12/20 deadline
- GLP 1s: accusations of "over-prescriptions" by payors force partnerships between employers and benefits design managers to decrease costs <sup>28</sup>
- Both Labcorp and Quest are in acquisition mode as hospitals continue the sale of lab assets, decreasing costs and freeing up capital for alternative investment<sup>29</sup>
- More payors view specialty pharmacy as the next viable revenue generator as other programs (like MA) face uncertainty<sup>30</sup>

#### **Providers:**

- ~70% of hospitals will receive readmission penalties less than 1% for the upcoming year, compared with 67% in 2023. Particularly, as Covid-era data is included in the analysis, higher rates of penalties may become more commonplace<sup>31</sup>
- Major credit rating agencies are docking system outlooks to account for cyberattack vulnerability (e.g., Ascension)<sup>32</sup>
- Through the lens of value-based care, some systems are creating joint ventures to improve access, care, and affordability (e.g., Henry Ford / Ascension (MI))<sup>33</sup>

#### Supply Chain / OEM:

- Stanford, Essentia, Winona, and Boulder Community have joined Civica, a generics purchasing consortium of hospitals and health systems focused on reducing shortages through longer-term purchasing contracts with manufacturers<sup>34</sup>
- Providers are continuing to navigate the IV fluid shortage caused by Hurricane Helene's destruction of a Baxter International production facility. As a result, many are rethinking their approaches to IV Bag use and may ultimately drive down go-forward demand for the product<sup>35</sup>
- PE-backed Medline files for IPO, a signal that public exits are attractive for 2025<sup>36</sup>

# PNC's Corporate Healthcare Index - Index Constituents and Periodic Return Data<sup>2,3</sup>

		Periodic Return Data as of End of Trading on 12/31/24						
		1-Month	3-Month	6-Month	1-Year	3-Year	5-Year	Year-to-Date
S&P	500 Index Value	(2.50%)	2.07%	7.71%	23.31%	22.71%	82.05%	23.31%
S&P	500 Health Care Sector Index Value	(6.36%)	(10.67%)	(5.62%)	0.90%	(2.61%)	35.06%	0.90%
PNC	's Corporate Healthcare Index Value	(1.32%)	(0.18%)	0.71%	24.50%	34.74%	127.06%	24.50%
Inde	x Constituents:							
Emer	ging Trends	-						
1.	23andMe Holding Co.	(8.45%)	(53.24%)	(58.46%)	(82.21%)	(97.52%)	-	(82.21%)
2.	agilon health, inc.	(9.09%)	(51.65%)	(70.95%)	(84.86%)	(92.90%)	-	(84.86%)
3.	Alphabet Inc.	12.04%	14.14%	3.93%	35.51%	29.08%	182.67%	35.51%
4.	Amazon.com, Inc.	5.53%	17.74%	13.53%	44.39%	29.66%	137.46%	44.39%
5.	AMN Healthcare Services, Inc.	(8.11%)	(43.57%)	(53.31%)	(68.06%)	(80.39%)	(61.61%)	(68.06%)
6.	CVS Health Corporation	(25.00%)	(28.61%)	(23.99%)	(43.15%)	(56.71%)	(39.57%)	(43.15%)
7.	JPMorgan Chase & Co.	(4.01%)	13.68%	18.52%	40.92%	51.18%	71.96%	40.92%
8.	Owens & Minor, Inc.	(2.97%)	(16.70%)	(3.19%)	(32.17%)	(70.02%)	152.80%	(32.17%)
9.	Walgreens Boots Alliance, Inc.	3.44%	4.13%	(22.86%)	(64.27%)	(82.14%)	(84.18%)	(64.27%)
10.	Walmart Inc.	(2.32%)	11.89%	33.44%	71.93%	89.93%	128.08%	71.93%
Healt	n Technology / IT							
11.	Oracle Corporation	(9.85%)	(2.21%)	18.02%	58.06%	88.91%	214.53%	58.06%
12.	Salesforce, Inc.	1.32%	22.15%	30.04%	27.05%	31.35%	105.56%	27.05%
13.	Teladoc Health, Inc.	(24.12%)	(0.98%)	(7.06%)	(57.82%)	(89.91%)	(89.14%)	(57.82%)
14.	Veradigm Inc.	(6.25%)	0.52%	2.63%	(7.05%)	(47.33%)	(0.66%)	(7.05%)
Payor								
15.	Centene Corporation	0.97%	(19.53%)	(8.63%)	(18.37%)	(28.07%)	(3.64%)	(18.37%)
16.	The Cigna Group	(18.25%)	(20.29%)	(16.47%)	(7.78%)	19.21%	35.04%	(7.78%)
17.	Elevance Health, Inc.	(9.35%)	(29.06%)	(31.92%)	(21.77%)	(21.12%)	22.14%	(21.77%)
18.	Humana Inc.	(14.40%)	(19.90%)	(32.10%)	(44.58%)	(45.91%)	(30.78%)	(44.58%)
19.	UnitedHealth Group Incorporated	(17.10%)	(13.48%)	(0.67%)	(3.91%)	0.06%	72.07%	(3.91%)
Pharr	naceuticals & Life Sciences							
20.	Biogen Inc.	(4.80%)	(21.11%)	(34.04%)	(40.91%)	(40.80%)	(48.46%)	(40.91%)
	Cencora, Inc.	(10.68%)	(0.18%)	(0.28%)	9.40%	68.50%	164.27%	9.40%
22.	Eli Lilly and Company	(2.94%)	(12.86%)	(14.73%)	32.44%	177.28%	487.38%	32.44%
	Johnson & Johnson	(6.70%)	(10.76%)	(1.05%)	(7.73%)	(15.70%)	(0.86%)	(7.73%)
24.	Merck & Co., Inc.	(2.13%)	(12.40%)	(19.64%)	(8.75%)	29.28%	9.38%	(8.75%)
	Moderna, Inc.	(3.44%)	(37.78%)	(64.99%)	(58.19%)	(83.23%)	112.58%	(58.19%)
26.	Pfizer Inc.	1.22%	(8.33%)	(5.18%)	(7.85%)	(53.92%)	(32.29%)	(7.85%)
27.	Roche Holding AG	0.00%	(5.58%)	2.40%	4.50%	(32.92%)	(18.63%)	4.50%
	Thermo Fisher Scientific Inc.	(1.77%)	(15.90%)	(5.93%)	(1.99%)	(21.50%)	60.13%	(1.99%)
Provid	ders							
	HCA Healthcare, Inc.	(8.27%)	(26.15%)	(6.58%)	10.89%	16.12%	103.06%	10.89%
30.	Surgery Partners, Inc.	(11.20%)	(34.34%)	(11.01%)	(33.82%)	(60.30%)	35.23%	(33.82%)
	Tenet Healthcare Corporation	(11.53%)	(24.05%)	(5.11%)	67.04%	56.94%	231.92%	67.04%
Suppl	y Chain / OEM							
	Cardinal Health, Inc.	(3.25%)	7.01%	20.29%	17.33%	127.22%	133.83%	17.33%
33.	DaVita Inc.	(10.00%)	(8.77%)	7.92%	42.75%	31.84%	99.32%	42.75%
	GE HealthCare Technologies Inc.	(6.06%)	(16.70%)	0.33%	1.11%	-	_	1.11%
	Hologic, Inc.	(9.32%)	(11.50%)	(2.91%)	0.90%	(4.00%)	38.08%	0.90%
	McKesson Corporation	(9.32%)	15.27%	(2.42%)	23.10%	129.38%	312.02%	23.10%
	Medtronic plc	(7.70%)	(11.27%)	1.49%	(3.03%)	(23.16%)	(29.59%)	(3.03%)
38.	Molina Healthcare, Inc.	(2.30%)	(15.53%)	(2.10%)	(19.45%)	(10.41%)	114.50%	(19.45%)
39.	Premier, Inc.	(7.42%)	6.00%	13.55%	(5.19%)	(48.77%)	(44.03%)	(5.19%)
40.	Solventum Corporation	(7.62%)	(5.25%)	24.92%	-	-	-	-

PNC HEALTHCARE

#### **Healthcare at PNC Overview**

#### **Contact Information**

## **Gyasi Chisley**

Head of Corporate Healthcare 312.338.2257 gyasi.chisley@pnc.com

## Christopher Ditta, CFA

VP, Corporate Healthcare 215.883.8937 christopher.ditta@pnc.com

## Brian R. Kelly

Head of PNC Healthcare 412.762.2976 brian.r.kelly@pnc.com

## Healthcare at PNC by the Numbers<sup>37</sup>

\$38B

in Capital Commitments to Healthcare Companies Across the US

50,000+

Healthcare Clients Served through PNC's Extensive Suite of Solutions

750+

Relationships with Private Equity Firms 500+

Employees Directly Serving Our Healthcare Clients

Years of Dedicated Sector Coverage via the PNC Healthcare Industry Vertical

\$13.0B

Healthcare Client Assets Under Management (AUM)38

## Brilliant begins here.



To learn more about how PNC Healthcare can deliver ideas, insights and solutions to help you move your business forward, contact your Relationship Manager or visit **pnc.com/healthcare**.

- Centers for Medicare & Medicaid Services
- Centers for Medicare & Medicaid Services
  Share price data is sourced from S&P CapitallQ as of January 1, 2025
  'PNC's Corporate Healthcare Index Value' is a weighted average of the constituents' share prices as of the end of trading on December 31, 2024. The Index is a market capitalization-weighted equity index. Rebalancing occurs on the last trading day of each fiscal quarter, most recently December 31, 2024. 'I's shown where there is insufficient share price history to calculate a percentage return over the specified time period.

  Market Commentary Page Sources: Becker's Hospital Review, Bloomberg, Fierce Healthcare, Healthcare Dive, HFMA, Modern Healthcare, Physicians Advocacy Institute, Pitchbook, Press Releases, Reuters, The Wall Street Journal
  HFMA: "David Johnson: 10 Forces Are Combining to Disrupt Healthcare's Status Quo" September 19, 2024
  Pitchbook: "03 2024 Healthcare Services PE Update" November 7, 2024

- Pitchbook: "Us 2024 Healthcare Services PE Update" November 7, 2024
  Modern Healthcare: "How Stalled Private Equity Oversight Bills May Sway M&A" October 4, 2024
  Modern Healthcare: "Why Big Retailers Are Hitting Roadblocks in Senior Care" November 11, 2024
  Modern Healthcare: "Why Big Retailers Are Hitting Roadblocks in Senior Care" November 11, 2024
  Healthcare Dive: "CMS Ordered to Recalculate United Healthcare's 2025 MAStars" November 25, 2024
  The Wall Street Journal: "Walgreens is in Talks to Sell Itself to Private-Equity Firm Sycamore Partners" December 11, 2024
  Reuters: "CVS Health to Lay Off Nearly, 2006 Employees in Cost-Cutting Push" October 1, 2024
  "With Unveiling of Longitude PHM, Execs Discuss Value-Based Care Goals" December 16, 2024
  Packards: "Total Peopleys CAP Bereau! A Legatis Sales" October 31, 2024

- Becker's: "Tenet Receives \$4.8B from 14 Hospital Sales" October 31, 2024
- Modern Healthcare: "Sutter Health Lays Out \$800 Million Outpatient Project" December 17, 2024 Fierce Healthcare
- 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. Becker's: "Anthem BCBS Walks Back Controversial Anesthesia Reimbursement Policy" - December 5, 2024

- Decker 3: Antiem Deb Waist Suck Controller and Antiem Learning Controller (1907) Bloom between 19, 2024 Modern Healthcare: "Why Health Systems Are Teaming Up to Create Companies" October 11, 2024 Bloomberg: "Citi, Apollo Join Forces in \$25 Billion Private Credit Push" September 26, 2024 Fierce Healthcare: "AMA Panel Changes Major Reporting Requirement for Remote Monitoring, Removing Barriers for the Industry" October 29, 2024 Kaiser Family Foundation: "Microsoft, Epic to Build New Al Tool Targeting Nurses' Workload" October 11, 2024
- Kaiser Family Foundation: "Microsoft, Epic to Build New Al Tool Targeting Nurses' Workload" October 11, 202 Hinge Health Press Release Modern Healthcare: "Salesforce, Epic and the Rise of CRM Programs" December 13, 2024 Modern Healthcare: "Medicare Advantage Insurers Bank on Special Needs Plans in 2025" October 9, 2024 Modern Healthcare: "Medicare Advantage Insurers Bank on Special Needs Plans in 2025" October 9, 2024 Modern Healthcare: "Medicaid Rate Hikes Boost Molina Healthcare" October 24, 2024 Modern Healthcare: "Medicaid Rate Hikes Boost Molina Healthcare" October 24, 2024 Modern Healthcare: "GLP-1 Costs Drive Employers to Specialty Benefits Vendors" September 25, 2024 Modern Healthcare: "GLP-1 Costs Drive Employers to Specialty Benefits Vendors" September 25, 2024 Modern Healthcare: "Elevance, Cigna, CVS Accelerate Push Into Specialty Pharmacy" October 30, 2024 Modern Healthcare: "More Hospitals to be Charged Readmissions Penalties: CMS" September 15, 2023 Modern Healthcare: "September 64, 2024

- $Modern\,Health care: "Ascension\,Cyberattack\,Prompts\,Revised\,Outlook\,from\,Moody's" September\,26, 2024$

- Modern HealthCare: Ascension Lyberatiack Frompis Revised Sutubus Nation Modern Health Press Release
  Modern HealthCare: "Stanford, Essentia and Other Health Systems Join Civica" December 5, 2024
  Modern HealthCare: "VF Luid Shortage Has Hospitals Rethinking Patient Hydration" November 29, 2024
  Modern HealthCare: "VF Luid Shortage Has Hospitals Rethinking Patient Hydration" November 29, 2024
  Modern HealthCare: "Modifies Submits Confidential Filing for Potentially Huge IPO" December 19, 2024
  Data as of December 31, 2024, except for HealthCare Client AUM data which is as of September 30, 2024
  "HealthCare Client Assets Under Management" represents assets managed by PNC Bank, NA and PNC Capital Advisors, LLC, an SEC-registered investment adviser and wholly-owned subsidiary of PNC Bank

PNC and PNC Bank are registered marks and Brilliantly Boring Since 1865 is a service mark of The PNC Financial Services Group, Inc. ("PNC")

This newsletter, including the Index was prepared for general information purposes only and is not intended as legal, tax or accounting advice or as recommendations to engage in any specific transaction, including with respect to any securities of PNC, and does not purport to be comprehensive. Under no circumstances should any information contained in this newsletter, including the Index, be used or considered as an offer or commitment, or a solicitation of an offer or commitment, to participate in any particular transaction or strategy. Opinions and forecasts expressed herein are subject to change without notice. Relevant information was obtained from sources deemed reliable. Such information is not guaranteed as to its accuracy. Any reliance upon any such information is solely and exclusively at your own risk. Please consult your own counsel, accountant, or other investment professional to discuss, or tailor a financial plan to, your specific situation. Neither PNC Bank nor any other subsidiary of The PNC Financial Services Group, Inc., will be responsible for any consequences of reliance upon any opinion or statement contained here, or any omission.

©2025 The PNC Financial Services Group, Inc. All rights reserved.